· Published by Health Canada · Official notice
This is a letter issued by the Marketed Health Products Directorate and the Therapeutic Products Directorate
Notice about Health Canada advisories
The Marketed Health Products and Therapeutic Products Directorates wish to draw your attention on a letter to prescribers published on February 10th 2003 by the Agence française de sécurité sanitaire des produits de santé (Afssaps) regarding important information on the use of amifostine (marketed as Ethyol in Canada).
The original French posting - available in French only
Dear healthcare professional:
Ethyol® is a proprietary medicine produced by MedImmune Oncology Inc. and distributed by Schering-Plough within the European Union.
Working in consultation with the Agence française de sécurité sanitaire des produits de santé (Afssaps), MedImmune Oncology Inc. and Schering-Plough wish to apprise you of important safety information concerning Ethyol® (amifostine) and to make certain recommendations concerning the management of severe cutaneous reactions.
The therapeutic indications for Ethyol® (amifostine) are:
IN CHEMOTHERAPY
IN RADIOTHERAPY
Since 1994, the date Ethyol® was authorized for marketing in Europe, approximately 128,000 patients have been treated with Ethyol® in Europe and around the world. Approximately 32,000 of these patients were given Ethyol® in the context of radiation protection measures.
During the past two years, an increased number of cutaneous reactions has been reported with Ethyol®, at the same time as its use has become more widespread, particularly in the context of radiation treatment. A total of 35 cases of severe cutaneous reactions (24 radiotherapy-related) have been reported around the world since Ethyol® came onto the market. These include cases of polymorphic erythema (8), Stevens-Johnson syndrome (10), toxic epidermal necrolysis (11), toxidermia (3), and bullous erythema (3). Four of these cases had a fatal outcome. The notification rate for severe cutaneous reactions with Ethyol® is estimated to be 6 to 9 cases per 10,000 in patients undergoing radiation treatment and 0.8 to 1 case per 10,000 in patients receiving chemotherapy. For 10 of the 35 reported cases, it would appear that administration of Ethyol® was continued despite the appearance of warning signs and symptoms of a cutaneous nature.
In keeping with their common commitment to ensure patient safety, MedImmune Oncology Inc. and Schering-Plough, in consultation with Afssaps, is informing health practitioners of the risk of cutaneous reactions and recommending strategies to manage such reactions should they arise.
Recommendations for the management of skin reactions associated with Ethyol®
Please report any undesirable side effect you may encounter to the Centre régional de pharmacovigilance (CRPV) with which you deal (contact information available on the website of Afssaps: www.afssaps.sante.fr or in the front pages of the Vidal dictionary).
If you have any questions or wish to obtain additional information concerning the use of Ethyol® please contact the Unité de Pharmacovigilance (01 41 06 36 36) or the Unité d'Information Médicale at Schering-Plough (01 55 46 44 80).
Sincerely,
original signed by
Dr. Alain RIMAILHO
Medical director
Any suspected adverse reactions can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0201C2
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the TPD web site or in The Canadian Compendium of Pharmaceuticals and Specialties.